Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
SIMPLE SUMMARY: Radioiodine therapy is the main treatment option for metastatic differentiated thyroid cancer (DTC). However, only half of these patients achieve (partial or complete) remission or have stable disease during long-term follow-up. In the remaining ones, disease progresses mainly as the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486510/ https://www.ncbi.nlm.nih.gov/pubmed/37686566 http://dx.doi.org/10.3390/cancers15174290 |
_version_ | 1785103023600566272 |
---|---|
author | Petranović Ovčariček, Petra Campenni, Alfredo de Keizer, Bart Deandreis, Desiree Kreissl, Michael C. Vrachimis, Alexis Tuncel, Murat Giovanella, Luca |
author_facet | Petranović Ovčariček, Petra Campenni, Alfredo de Keizer, Bart Deandreis, Desiree Kreissl, Michael C. Vrachimis, Alexis Tuncel, Murat Giovanella, Luca |
author_sort | Petranović Ovčariček, Petra |
collection | PubMed |
description | SIMPLE SUMMARY: Radioiodine therapy is the main treatment option for metastatic differentiated thyroid cancer (DTC). However, only half of these patients achieve (partial or complete) remission or have stable disease during long-term follow-up. In the remaining ones, disease progresses mainly as they become radioiodine-refractory. The diagnostics of radioiodine-refractory disease are extensively debated. The introduction of novel tracers besides radioiodine isotopes ((131)I, (123)I, and (124)I) and 2-[(18)F]fluoro-2-deoxy-D-glucose ([(18)F]FDG) opens new options for the diagnostics and therapy of this subgroup of DTC patients. Prostate-specific membrane antigen (PSMA) ligands, fibroblast activation protein inhibitors (FAPI), and somatostatin receptor-targeted radiopharmaceuticals appear to be new potential theranostics tracers. In this review, we will elaborate on the role of these radiopharmaceuticals in the management of radioiodine-refractory disease. ABSTRACT: Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is essential for disease evaluation and further management. The most commonly used tracers are [(18)F]FDG and isotopes of radioiodine. Several other radiopharmaceuticals may be used as well, with different diagnostic performances. This review article aims to summarize radiopharmaceuticals used in patients with radioiodine-refractory DTC (RAI-R DTC), focusing on their different molecular pathways. Additionally, it will demonstrate possible applications of the theranostics approach to this subgroup of metastatic DTC. |
format | Online Article Text |
id | pubmed-10486510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104865102023-09-09 Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer Petranović Ovčariček, Petra Campenni, Alfredo de Keizer, Bart Deandreis, Desiree Kreissl, Michael C. Vrachimis, Alexis Tuncel, Murat Giovanella, Luca Cancers (Basel) Review SIMPLE SUMMARY: Radioiodine therapy is the main treatment option for metastatic differentiated thyroid cancer (DTC). However, only half of these patients achieve (partial or complete) remission or have stable disease during long-term follow-up. In the remaining ones, disease progresses mainly as they become radioiodine-refractory. The diagnostics of radioiodine-refractory disease are extensively debated. The introduction of novel tracers besides radioiodine isotopes ((131)I, (123)I, and (124)I) and 2-[(18)F]fluoro-2-deoxy-D-glucose ([(18)F]FDG) opens new options for the diagnostics and therapy of this subgroup of DTC patients. Prostate-specific membrane antigen (PSMA) ligands, fibroblast activation protein inhibitors (FAPI), and somatostatin receptor-targeted radiopharmaceuticals appear to be new potential theranostics tracers. In this review, we will elaborate on the role of these radiopharmaceuticals in the management of radioiodine-refractory disease. ABSTRACT: Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is essential for disease evaluation and further management. The most commonly used tracers are [(18)F]FDG and isotopes of radioiodine. Several other radiopharmaceuticals may be used as well, with different diagnostic performances. This review article aims to summarize radiopharmaceuticals used in patients with radioiodine-refractory DTC (RAI-R DTC), focusing on their different molecular pathways. Additionally, it will demonstrate possible applications of the theranostics approach to this subgroup of metastatic DTC. MDPI 2023-08-27 /pmc/articles/PMC10486510/ /pubmed/37686566 http://dx.doi.org/10.3390/cancers15174290 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Petranović Ovčariček, Petra Campenni, Alfredo de Keizer, Bart Deandreis, Desiree Kreissl, Michael C. Vrachimis, Alexis Tuncel, Murat Giovanella, Luca Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer |
title | Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer |
title_full | Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer |
title_fullStr | Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer |
title_full_unstemmed | Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer |
title_short | Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer |
title_sort | molecular theranostics in radioiodine-refractory differentiated thyroid cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486510/ https://www.ncbi.nlm.nih.gov/pubmed/37686566 http://dx.doi.org/10.3390/cancers15174290 |
work_keys_str_mv | AT petranovicovcaricekpetra moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer AT campennialfredo moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer AT dekeizerbart moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer AT deandreisdesiree moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer AT kreisslmichaelc moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer AT vrachimisalexis moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer AT tuncelmurat moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer AT giovanellaluca moleculartheranosticsinradioiodinerefractorydifferentiatedthyroidcancer |